Search

Displaying results 7201 - 7210 of 10000 in total
  1. Drug

    Tyramine

    go.drugbank.com/drugs/DB08841
    InvestigationalNutraceutical

    There have been reports of hypertensive crisis in patients ingesting tyramine-rich diet in conjunction with monoamine oxidase inhibitors (MAOIs). … An important characteristic of this product is its impediment to cross the blood-brain barrier which restrains its side effects to only nonpsychoactive peripheral sympathomimetic effects.

  2. Drug

    Peginterferon alfacon-1

    go.drugbank.com/drugs/DB05860
    Experimental

    PEGylation is a technology for the chemical attachment of polyethylene glycol (PEG) polymer chains to a broad range of drug substances such as peptides and proteins including antibody fragments; small molecules, and other drugs. [Inferge...

  3. Drug

    ADX-10061

    go.drugbank.com/drugs/DB05419
    Experimental

    ADX10061 is a potent, selective antagonist of the dopamine D1 receptor. It is developed by Addex Pharmaceuticals for the treatment of nicotine dependence.

  4. Drug

    Medetomidine

    go.drugbank.com/drugs/DB11428
    ExperimentalVet approved

    In the United States, it is currently approved for its veterinary use in dogs and distributed by Pfizer Animal Health. In Canada, medetomidine is distributed by Novartis Animal Health. … Medetomidine is an intravenously available alpha-2 adrenergic agonist. The drug has been developed by Orion Pharma.

  5. Drug

    Human growth hormone-releasing peptide 3

    go.drugbank.com/drugs/DB19227
    Investigational

    Human growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance

  6. Drug

    Abarelix

    go.drugbank.com/drugs/DB00106
    ApprovedWithdrawn

    Praecis announced in June 2006 that it was voluntarily withdrawing the drug from the market.

  7. Drug

    T487

    go.drugbank.com/drugs/DB05474
    Experimental

    The formulation is administered orally and has anti-inflammatory effects in conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.

  8. Drug

    XC221

    go.drugbank.com/drugs/DB16503
    Investigational

    XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

  9. Drug

    SGS518

    go.drugbank.com/drugs/DB05042
    Experimental

    SGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).

  10. Drug

    EGT-301

    go.drugbank.com/drugs/DB17649
    Experimental

    It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome